American Heart Association official publications and updates

Eli Lilly's Zepbound Shows 38% Reduction in Heart Failure Risk in Obesity-Related Phase 3 Trial with 700 Participants

Aug 1, 2024, 11:00 AM

Eli Lilly's weight-loss drug Zepbound has shown significant cardiovascular benefits in a recent late-stage study. The SUMMIT phase 3 trial, which involved over 700 participants, demonstrated that tirzepatide, the active ingredient in Zepbound, reduced the risk of heart failure outcomes by 38% compared to a placebo. The study also highlighted improvements in heart failure symptoms and physical limitations among patients with obesity-related heart failure and preserved ejection fraction. These findings mark the first trial to establish the long-term cardiovascular benefits of Zepbound, potentially positioning it as a leading treatment for patients with heart failure and obesity.